CALR and synovial sarcoma: RA is a risk factor for LPD; and SS associated with EBV and anti-Ro/SS-A antibodies might play a role in facilitating LPD, suggesting the need for caution when administering DMARDs, which are believed to be associated with LPD development in patients with RA and sSS and/or positivity for anti-Ro/SS-A antibodies.